<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">11212082</PMID>
      <DateCompleted>
        <Year>2001</Year>
        <Month>04</Month>
        <Day>05</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2019</Year>
        <Month>05</Month>
        <Day>13</Day>
      </DateRevised>
      <Article PubModel="Print">
        <Journal>
          <ISSN IssnType="Print">1355-4786</ISSN>
          <JournalIssue CitedMedium="Print">
            <Volume>7</Volume>
            <Issue>1</Issue>
            <PubDate>
              <Year>2001</Year>
              <Season>Jan-Feb</Season>
            </PubDate>
          </JournalIssue>
          <Title>Human reproduction update</Title>
          <ISOAbbreviation>Hum Reprod Update</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Efficacy of nafarelin in assisted reproductive technology: a meta-analysis.</ArticleTitle>
        <Pagination>
          <StartPage>92</StartPage>
          <EndPage>101</EndPage>
          <MedlinePgn>92-101</MedlinePgn>
        </Pagination>
        <Abstract>
          <AbstractText>A systematic review identified nine randomized, controlled trials (both published and unpublished) which assessed the efficacy of nafarelin during IVF compared with other gonadotrophin-releasing hormone (GnRH) agonists. The trials included 1,014 women (nafarelin n = 597) in protocols employing three different dosage regimens, long and short stimulation protocols, and three comparative GnRH agonists (buserelin n = 348; triptorelin n = 14, and leuprolide n = 55). The meta-analysis of the data showed that pregnancy rates per embryo transfer with nafarelin were equivalent to those obtained with other GnRH agonists. Nafarelin and other agonists were also comparable in terms of several intermediate IVF outcomes, including fertilization rates, number of oocytes retrieved, peak oestradiol concentrations, and cycle cancellations. Women treated with nafarelin required fewer ampoules of human menopausal gonadotrophin (HMG)/FSH for ovarian stimulation and fewer days of stimulation. Safety results from both the meta-analysis and a qualitative analysis of 12 additional reports suggested that adverse effects were within the accepted tolerance range; the most frequent adverse effects were hypo-oestrogenic symptoms. In conclusion, the overall efficacy of nafarelin was equivalent to that of other GnRH agonists. The possibility that the reduced gonadotrophin requirements in women taking nafarelin will translate into cost savings per IVF treatment cycle requires further study.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Wong</LastName>
            <ForeName>J M</ForeName>
            <Initials>JM</Initials>
            <AffiliationInfo>
              <Affiliation>Global Outcomes Research, Pharmacia Corporation, Skokie, IL 60077, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Forrest</LastName>
            <ForeName>K A</ForeName>
            <Initials>KA</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Snabes</LastName>
            <ForeName>S Z</ForeName>
            <Initials>SZ</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Zhao</LastName>
            <ForeName>S Z</ForeName>
            <Initials>SZ</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Gersh</LastName>
            <ForeName>G E</ForeName>
            <Initials>GE</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Kennedy</LastName>
            <ForeName>S H</ForeName>
            <Initials>SH</Initials>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016430">Clinical Trial</PublicationType>
          <PublicationType UI="D003160">Comparative Study</PublicationType>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D017418">Meta-Analysis</PublicationType>
          <PublicationType UI="D016449">Randomized Controlled Trial</PublicationType>
          <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
          <PublicationType UI="D000078182">Systematic Review</PublicationType>
        </PublicationTypeList>
      </Article>
      <MedlineJournalInfo>
        <Country>England</Country>
        <MedlineTA>Hum Reprod Update</MedlineTA>
        <NlmUniqueID>9507614</NlmUniqueID>
        <ISSNLinking>1355-4786</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D006728">Hormones</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>1X0094V6JV</RegistryNumber>
          <NameOfSubstance UI="D017274">Nafarelin</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>33515-09-2</RegistryNumber>
          <NameOfSubstance UI="D007987">Gonadotropin-Releasing Hormone</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>61489-71-2</RegistryNumber>
          <NameOfSubstance UI="D008596">Menotropins</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>9002-68-0</RegistryNumber>
          <NameOfSubstance UI="D005640">Follicle Stimulating Hormone</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D004624" MajorTopicYN="N">Embryo Transfer</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005307" MajorTopicYN="Y">Fertilization in Vitro</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005640" MajorTopicYN="N">Follicle Stimulating Hormone</DescriptorName>
          <QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007987" MajorTopicYN="N">Gonadotropin-Releasing Hormone</DescriptorName>
          <QualifierName UI="Q000819" MajorTopicYN="N">agonists</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006728" MajorTopicYN="N">Hormones</DescriptorName>
          <QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
          <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008596" MajorTopicYN="N">Menotropins</DescriptorName>
          <QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D017274" MajorTopicYN="N">Nafarelin</DescriptorName>
          <QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
          <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D011247" MajorTopicYN="N">Pregnancy</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D016032" MajorTopicYN="N">Randomized Controlled Trials as Topic</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2001</Year>
          <Month>2</Month>
          <Day>24</Day>
          <Hour>12</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2001</Year>
          <Month>4</Month>
          <Day>6</Day>
          <Hour>10</Hour>
          <Minute>1</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2001</Year>
          <Month>2</Month>
          <Day>24</Day>
          <Hour>12</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">11212082</ArticleId>
        <ArticleId IdType="doi">10.1093/humupd/7.1.92</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
